Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.238 EUR 0.85%
Market Cap: 29.7m EUR

EV/EBIT
Enterprise Value to EBIT

-1
Current
-1.9
Median
3.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-1
=
Enterprise Value
38.5m EUR
/
EBIT
-37.1m EUR
EBIT Growth EV/EBIT to Growth
FR
Gensight Biologics SA
PAR:SIGHT
Average EV/EBIT: 21.7
Negative Multiple: -1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 527.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.8
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.2
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.9
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.8
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.9
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 413.4 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-1.3
2-Years Forward
EV/EBIT
-1.3
3-Years Forward
EV/EBIT
-1.2